Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film

Fig. 2

Effect of topical carbonic anhydrase inhibitors (CAIs) on the superoxide dismutase (SOD) activity in the tear film. C – control group (n = 25); DL – patients with primary open-angle glaucoma (POAG) using topical dorzolamide (Nodofree, Polfa Warszawa) (n = 14); DL + BAC – patients with POAG using topical dorzolamide + benzalkonium chloride (BAC) (Trusopt, Santen) (n = 16); DL + BAC – patients with POAG using topical brinzolamide + BAC (Azopt, Novartis) (n = 17). Results are presented as means ± SEM. ** p < 0.01 – statistically significantly different from the C group

Back to article page